JP2022513597A5 - - Google Patents

Info

Publication number
JP2022513597A5
JP2022513597A5 JP2021525191A JP2021525191A JP2022513597A5 JP 2022513597 A5 JP2022513597 A5 JP 2022513597A5 JP 2021525191 A JP2021525191 A JP 2021525191A JP 2021525191 A JP2021525191 A JP 2021525191A JP 2022513597 A5 JP2022513597 A5 JP 2022513597A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antisense oligonucleotide
administered
dose
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513597A (ja
JP7612575B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065936 external-priority patent/WO2020123783A1/en
Publication of JP2022513597A publication Critical patent/JP2022513597A/ja
Publication of JP2022513597A5 publication Critical patent/JP2022513597A5/ja
Priority to JP2024213950A priority Critical patent/JP2025023319A/ja
Application granted granted Critical
Publication of JP7612575B2 publication Critical patent/JP7612575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525191A 2018-12-14 2019-12-12 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法 Active JP7612575B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213950A JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862779916P 2018-12-14 2018-12-14
US62/779,916 2018-12-14
US201962807603P 2019-02-19 2019-02-19
US62/807,603 2019-02-19
US201962840879P 2019-04-30 2019-04-30
US62/840,879 2019-04-30
PCT/US2019/065936 WO2020123783A1 (en) 2018-12-14 2019-12-12 Compositions and methods for treating and preventing amyotrophic lateral sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213950A Division JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022513597A JP2022513597A (ja) 2022-02-09
JP2022513597A5 true JP2022513597A5 (cg-RX-API-DMAC10.html) 2022-10-27
JP7612575B2 JP7612575B2 (ja) 2025-01-14

Family

ID=69160351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525191A Active JP7612575B2 (ja) 2018-12-14 2019-12-12 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法
JP2024213950A Pending JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213950A Pending JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Country Status (20)

Country Link
US (1) US20220073930A1 (cg-RX-API-DMAC10.html)
EP (1) EP3894557A1 (cg-RX-API-DMAC10.html)
JP (2) JP7612575B2 (cg-RX-API-DMAC10.html)
KR (2) KR102821047B1 (cg-RX-API-DMAC10.html)
CN (3) CN113330116A (cg-RX-API-DMAC10.html)
AU (2) AU2019396522B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021011334A2 (cg-RX-API-DMAC10.html)
CA (1) CA3115549A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021001136A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021008187A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210384A (cg-RX-API-DMAC10.html)
IL (1) IL283833A (cg-RX-API-DMAC10.html)
JO (1) JOP20210143A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021005086A (cg-RX-API-DMAC10.html)
MY (1) MY209775A (cg-RX-API-DMAC10.html)
PH (1) PH12021551365A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202103415WA (cg-RX-API-DMAC10.html)
TW (1) TWI906204B (cg-RX-API-DMAC10.html)
UY (1) UY38506A (cg-RX-API-DMAC10.html)
WO (1) WO2020123783A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
JP7506606B2 (ja) 2018-01-25 2024-06-26 バイオジェン・エムエイ・インコーポレイテッド 脊髄性筋萎縮症を治療する方法
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
EP3924739A1 (en) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarkers of progressive multifocal leukoencephalopathy
KR20230172502A (ko) * 2021-03-31 2023-12-22 바이오젠 엠에이 인코포레이티드 근위축성 측삭경화증의 치료
WO2025045130A1 (zh) * 2023-08-29 2025-03-06 石药集团中奇制药技术(石家庄)有限公司 一种抑制sod1基因表达的dsrna分子及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
WO2013134403A1 (en) * 2012-03-06 2013-09-12 The Washington University Method of treating neurodegenerative diseases with microrna regulators
SI3119888T1 (sl) * 2014-03-19 2021-11-30 Ionis Pharmaceuticals, Inc. Sestavki za moduliranje izražanja ataksina 2
HUE050704T2 (hu) 2014-04-01 2020-12-28 Biogen Ma Inc Összetételek a SOD-1 expressziójának modulálására
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
EP3618839A4 (en) * 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
WO2018218219A1 (en) * 2017-05-26 2018-11-29 University Of Miami Determining onset of amyotrophic lateral sclerosis

Similar Documents

Publication Publication Date Title
JP7198298B2 (ja) Sod-1発現を調節するための組成物
RU2566724C9 (ru) Композиции и способы модуляции smn2 сплайсинга у субъекта
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
JP2021104035A (ja) アタキシン2の発現を調節するための組成物
JP2022501040A (ja) 17β−HSD13型(HSD17B13)の発現を阻害するためのRNAi剤、その組成物、および使用方法
US20140378533A1 (en) Modulation of rna by repeat targeting
TW201920227A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
HK1246648A1 (en) Compositions and methods for modulation of smn2 splicing in a subject
CN104994884B (zh) 对脂蛋白脂肪酶缺乏(lpld)群体中的载脂蛋白c-iii(apociii)表达的调节
JP2022527105A (ja) Ube3a-atsを調節するための化合物及び方法
JP7612575B2 (ja) 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法
TW202016305A (zh) Apol1表現之調節劑
KR20230108728A (ko) 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
CN119365598A (zh) 用于治疗单基因神经发育障碍的组合物和方法
EP4100022B1 (en) Sirna, medical compositions, and methods for treating diabetes using the same
RU2021112868A (ru) Составы и способы лечения и предотвращения бокового амиотрофического склероза
RU2024121642A (ru) Составы и способы лечения и предотвращения бокового амиотрофического склероза
CN121358862A (zh) 用于治疗肾脏疾病的组合物和方法
WO2019161294A1 (en) Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm)
HK40120557A (en) Compounds and methods for modulating angiotensinogen expression
CN121152878A (zh) 用于抑制补体因子B (CFB)表达的RNAi剂、其药物组合物和使用方法
HK40054232B (en) Modulators of pnpla3 expression
HK40000192B (en) Compositions and methods for modulation of smn2 splicing in a subject
HK40025555A (en) Compositions and methods for modulation of smn2 splicing in a subject